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In the study presented here, we investigated the pos-
sible interactions between CD95 (Fas/APO-1) and Bcl-2
by studying the effects of Bcl-2 on the modulation of
cellular pathways activated by CD95 using HeLa cells as
amodel system.We report that stable expression of Bcl-2
in HeLa cells is associated with multiple phenotypic
changes. Treatment of HeLa cells with anti-CD95 mono-
clonal antibody (mAb) resulted in preferential degrada-
tion of lamin B compared with lamins A and C. Signifi-
cant lamin B degradation was detected as early as 1 h
after anti-CD95 mAb treatment. In contrast, lamins A
and C as well as actin remained unchanged until 4 h
after treatment with anti-CD95 mAb, a time point that
correlated with the period of DNA fragmentation. These
results indicate that selective degradation of lamin B is
an early cellular event in response to activation of the
CD95 pathway and that it precedes DNA fragmentation.
Overexpression of Bcl-2 resulted in prevention of lamin
B degradation and DNA fragmentation into oligonucleo-
some fragments in response to the apoptotic signal by
anti-CD95 mAb. In addition, in Bcl-2-overexpressing
cells that were protected against apoptosis, anti-CD95
mAb-induced cleavage of poly(ADP-ribose) polymerase
was completely blocked. Overexpression of Bcl-2 also
resulted in restoration of the CD95-mediated signaling
pathway involving activation of the transcription factor
NF-kB (p50/RelA). These findings suggest that Bcl-2 pre-
vents apoptosis in part by preventing the degradation of
major nuclear polypeptides such as lamin B and poly-
(ADP-ribose) polymerase. In addition, our results dem-
onstrate that CD95-mediated signaling involves activa-
tion of NF-kB (p50/RelA).
In recent years, it has become accepted that programed cell
death or apoptosis is a normal physiological phenomenon that
plays an important role in the regulation of tissue develop-
ment, metamorphosis, organ involution, and homeostasis (1, 2).
The deregulation of apoptosis has been shown to contribute to
the pathogenesis of a number of human diseases including
cancer and autoimmune disorders (3, 4). Activation of apoptosis
is dependent on both pre-exiting proteins and de novo protein
synthesis and is characterized in part by nuclear membrane
blebbing, chromatin condensation, and internucleosomal DNA
degradation into oligonucleosome fragments (1). In addition,
we and others have shown that chromatin condensation during
apoptosis is accompanied by degradation of the nuclear lamins,
which are involved in maintaining the integrity of the nuclear
envelope (4–8), and also by degradation of poly(ADP-ribose)
polymerase (PARP)1 (9, 10), which is thought to be involved in
DNA repair.
The occurrence of apoptosis is a highly regulated process.
The human CD95 receptor, a member of the TNF/nerve growth
factor receptor superfamily, is a cell-surface antigen that trig-
gers apoptosis when activated by agonist anti-CD95 mAb and
by a specific CD95 ligand (CD95L) (11). Recent deletion studies
have identified an 80-residue homology region (death domain)
in the carboxyl-terminal part of CD95 and the TNF receptor
(12, 13) that appears to play an essential role in transduction of
the apoptotic signal. The TNF receptor still retains its apo-
ptotic activity when this region is replaced with the death do-
main of CD95, raising the possibility of a similar mechanism(s)
in induction of apoptosis by these two receptors. Despite this
structural similarity, data from the literature suggest that
CD95 and TNF receptors may utilize distinct signal transduc-
tion pathways, as TNF (but not CD95) induces activation of the
transcription factor NF-kB (14, 15). In spite of these differ-
ences, both anti-CD95 mAb and TNF trigger apoptosis. The
common pathway of cell death appears to involve activation of
interleukin-1b-converting enzyme (ICE) or ICE/ced-3 family
proteases (16–18). The observations that overexpression of ICE
in mammalian cells potentiates CD95-mediated apoptosis and
that inhibition of ICE activity suppresses CD95-mediated ap-
optosis in human cells (18) illustrate the critical importance of
this protease pathway in CD95-induced apoptosis.
Another important regulator of apoptosis is Bcl-2, 26-kDa
protein that protects cells against apoptosis in a number of
experimental systems (1). A number of Bcl-2 homologs have
been identified, including Bcl-XL and BAG-1, which suppress
apoptosis, and Bcl-Xs, Bax, and Bad, which promote apoptosis.
Current models suggest that the ratios of these anti- to pro-
apoptotic proteins may play a regulatory role in apoptosis (19–
21). Recent studies suggest that cells derived from a variety of
human cancers may have a decreased ability to undergo apo-
ptosis in response to various physiological stimuli (3, 4), and
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thus, a defect in apoptosis may be involved in the aberrant
survival and/or development of cancer.
The mechanism by which Bcl-2 exerts its anti-apoptotic ef-
fect is not as yet fully resolved. One view suggests that Bcl-2
may function as an antioxidant and blocks oxidative damage
induced by reactive oxygen species generated during apoptosis
(1). Accordingly, overexpression of Bcl-2 has been shown to
inhibit activation of NF-kB caused by oxidative stress (22). In
contrast, recent studies have shown that apoptosis by a num-
ber of agents including anti-CD95 mAb (23) can be induced
even in the absence of reactive oxygen, and Bcl-2 could effec-
tively inhibit such apoptosis (24, 25). There is also evidence
indicating that activation of NF-kB is not exclusively restricted
to oxidative damage, as TNF has been shown to induce NF-kB
in T lymphocytes without involving reactive oxygen (25). Fur-
thermore, Bcl-2 has been shown to protect mouse L929 cells
from TNF-induced oxidative damage and apoptosis without
interfering with activation of NF-kB (26). In brief, these obser-
vations suggest that Bcl-2 might protect cells without altering
signaling pathways activated during apoptosis.
In this study, we investigated the regulatory interactions
between the CD95 and Bcl-2 pathways. We report that the
deregulation of Bcl-2 in HeLa cells results in several important
phenotypic changes that accompany the inhibition of apoptosis.
First, we examined the effect of Bcl-2 on lamin cleavage during
CD95-mediated apoptosis. We observed that CD95-mediated
DNA fragmentation is preceded by selective degradation of
lamin B (compared with lamins A and C) and that Bcl-2 over-
expression inhibits lamin degradation as well as DNA fragmen-
tation. Second, we examined the kinetics of PARP cleavage in
CD95-activated cells and demonstrated that Bcl-2 overexpres-
sion completely blocked anti-CD95 mAb-induced cleavage of
PARP. Finally, we observed that treatment of Bcl-2-expressing
cells with anti-CD95 mAb was accompanied by activation of
NF-kB (p50/RelA) and also de novo synthesis of NF-kB-regu-
lated proteins. These findings indicate that Bcl-2 deregulation
is accompanied by multiple phenotypic changes, each of which
might contribute to the inhibition of apoptosis.
MATERIALS AND METHODS
Cells and Expression of Bcl-2—HeLa cells (27, 28) were maintained
in modified Eagle’s medium supplemented with 10% fetal bovine se-
rum. HeLa cells at a density of 106 cells/100-mm diameter plate were
transfected with plasmid DNA containing the full-length human Bcl-2
cDNA and a selectable marker, the neomycin phosphotransferase gene
(pSSFbcl-2) (29), by calcium phosphate precipitation procedures as
described (30). Expression of Bcl-2 in individually isolated clones was
determined by immunoblotting with a Bcl-2 mAb (Neomarkers, Inc.).
Once a stable cell line from each clone had been established, the drug
was removed from the culture medium. The clonal lines have been
maintained in drug-free medium since then, and expression of Bcl-2
was periodically examined.
Induction of Apoptosis—Anti-human CD95 mAb (clone CH-11) (31)
was obtained from Kamiya Biochemical. Recombinant human interfer-
on-g (specific activity 5 4 3 106 IU/mg) was obtained from Genentech
Inc. For induction of apoptosis, cells were treated with interferon-g (500
IU/ml) for 12 h, and some cultures were treated with anti-CD95 mAb
(100 ng/ml) from 1–6 h as described (31). After the desired treatment,
both floating and attached cells were collected and analyzed.
Cell Extracts and Immunoblotting—All experiments were performed
with cells in logarithmic phase by controlling the plating density. Via-
bility of cells was assayed by trypan blue dye exclusion. Cells extracts
were prepared as described (27). Cell lysates containing equal amounts
of total protein (15–25 mg) were resolved on a 10% SDS-polyacrylamide
gel, followed by probing with the desired antibodies (27), and immune
complexes were detected using an ECL method (Amersham Corp.). For
immunoblotting of lamins, we used well characterized chicken antibod-
ies to lamins A and C (recognized by the same antibody) and lamin B
(32). For PARP immunoblotting, we used a mAb (C-2-10) against PARP
(33). As a internal control, the same blot was reprobed with an unre-
lated actin antibody (Sigma). Low molecular mass colored markers
(Amersham Corp.) were used as molecular mass standards. Quantita-
tion of specific protein bands was performed using a protein data base
scanner (Molecular Dynamics, Inc.).
DNA Fragmentation Assay—For the DNA fragmentation assay, low
molecular size DNA was isolated. Briefly, cells (3 3 106/plate) were
seeded in 100-mm plates and treated as desired. Both floating and
attached cells were scraped and collected in medium, washed three
times with phosphate-buffered saline, and resuspended in 1 ml of lysis
buffer (20 mM Tris-HCl, pH 8, 10 mM EDTA, pH 8, and 0.5% Triton
X-100). After a 30-min incubation on ice, the lysates were centrifuged at
12,000 rpm in an Eppendorf microcentrifuge for 10 min. Low molecular
size DNA in the supernatant was extracted with an equal volume of
phenol/chloroform for 1 h at 4 °C. Ammonium acetate (2 M) was added
to the aqueous phase, and DNA was precipitated with 2 volumes of
ethanol at 220 °C overnight. DNA was treated with RNase A (1 mg/ml)
at 37 °C for 1 h, and total DNAwas analyzed using 1.5% agarose gel and
visualized by ethidium bromide staining of gel.
Nuclear Extract Preparation and Electrophoretic Mobility Shift As-
say (EMSA)—HeLa cells were washed with phosphate-buffered saline
and then collected by centrifugation. Nuclear extracts were prepared as
described previously (34). EMSA was performed by incubating the
nuclear extracts (5 mg) with a 32P-radiolabeled high affinity palindromic
kB probe, kB-pd (coding stand sequence, 59-CAACGGCAGGGGGAAT-
TCCCCTCTCTCCTT-39). The DNA-protein complexes were resolved on
5% native polyacrylamide gels (34). For antibody “supershift” assays, 1
ml of anti-peptide antiserum specifically recognizing each of the NF-
kB subunits was added to the EMSA reaction 10 min prior to
electrophoresis.
RESULTS
Effect of Anti-CD95 mAb on Integrity of Lamins—To explore
the possible involvement of nuclear envelope proteins during
CD95-mediated apoptosis, we examined the effect of CD95
activation on the integrity of lamins. Previous results have
demonstrated that proteolytic cleavage of lamins occurs in
several cell types undergoing apoptosis (see Introduction) and
is mediated by an ICE family member (7). The results in Fig.
1A demonstrate the kinetics of anti-CD95 mAb-mediated deg-
radation of DNA in HeLa cells. As expected, treatment of HeLa
cells with anti-CD95 mAb stimulated internucleosomal DNA
degradation into oligonucleosome fragments in a time-depend-
ent manner starting at 4 h post-treatment (Fig. 1A, lane 6). The
results of a quantitative enzyme-linked immunosorbent assay-
based apoptotic assay (30) that measures cytoplasmic histone-
bound DNA complexes generated during apoptotic DNA frag-
mentation demonstrated lack of DNA fragmentation up to 3 h
after anti-CD95 mAb treatment (data not shown). To examine
the relationship between the degradation of DNA and lamins,
we analyzed the cellular content of the lamins by immunoblot-
ting HeLa cells treated with or without anti-CD95 mAb. As
shown in Fig. 1 (B and C), treatment of HeLa cells with anti-
CD95 mAb resulted in preferential degradation of lamin B
compared with lamins A and C. Significant lamin B degrada-
tion (62% degradation compared with levels in control cells)
was detected as early as 1 h after anti-CD95 mAb treatment. In
contrast, lamins A and C as well as actin remained unchanged
until 4 h after treatment with anti-CD95 mAb, a time point
that correlated with the period of DNA fragmentation. These
results indicate that selective degradation of lamin B is an
early cellular event in response to activation of the CD95
pathway.
Bcl-2 Prevents CD95-mediated Degradation of Lamin B—To
further explore the possible involvement of lamin B in anti-
CD95 mAb-mediated apoptosis, we next examined the effect of
Bcl-2 on anti-CD95 mAb-mediated lamin B degradation and
DNA fragmentation. For these studies, HeLa cells were trans-
fected with a Bcl-2 expression vector (29), and a number of
clonal cell lines stably overexpressing Bcl-2 were generated.
Fig. 2A shows the levels of Bcl-2 protein in three out of seven
isolated clones, HeLa/Bcl-2.1 (lane 2), HeLa/Bcl-2.7 (lane 3),
and HeLa/Bcl-2.5 (lane 4). Clones 1 and 7 express the highest
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(4–6-fold) levels of Bcl-2 compared with the levels detected in
the parental HeLa cells (Fig. 1A, lane 1) or in the control
HeLa/PKR.w1 neo clone (lane 5) expressing an unrelated gene.
To compare the fate of the lamins in the control and Bcl-2-
expressing HeLa cells, cells were treated with anti-CD95 mAb.
As shown in Fig. 2, Bcl-2 overexpression prevented the degra-
dation of lamin B (panel C) and DNA fragmentation into oligo-
nucleosome fragments (panel B) in response to the apoptotic
signal by anti-CD95 mAb (see also Fig. 4, lanes 8 and 9). The
observed protection of cells from anti-CD95 mAb-mediated ap-
optosis resulted from overexpression of Bcl-2 since it was de-
tected in both clones 1 and 7, but not in control HeLa cells or in
HeLa cells overexpressing an unrelated PKR/neo gene (HeLa/
PKR.w1 cells) (data not shown). Taken together, these results
suggest that (i) CD95-mediated degradation of DNA is pre-
ceded by selective degradation of lamin B, and (ii) degradation
of lamin B, like DNA fragmentation, can be effectively blocked
by Bcl-2 expression.
Bcl-2 Prevents CD95-mediated Degradation of PARP—Pre-
vious studies have shown that PARP is also cleaved by the ICE
family proteases as an early event during apoptosis in a num-
ber of cell types (5, 9, 10). As illustrated in Fig. 3A, incubation
of HeLa cells with anti-CD95 mAb resulted in a time-depend-
ent cleavage of PARP and the appearance of an immunoreac-
tive 85-kDa cleavage product. Quantitation of uncleaved PARP
indicated that anti-CD95 mAb cleaved ;22 and 53% of PARP
by 1 and 1.5 h post-treatment, respectively, suggesting that the
cleavage of PARP is also an early cellular marker during CD95-
induced apoptosis. More important, in Bcl-2-overexpressing
HeLa cells that were protected against apoptosis, anti-CD95
mAb-induced cleavage of PARP was completely blocked (Fig.
3B; see also Fig. 4, lanes 8 and 9). Taken together, the results
from Figs. 1–3 suggest that the enhanced survival of Bcl-2-
overexpressing HeLa cells in response to the apoptotic CD95
signal is correlated with the suppression of degradation of
lamin B and PARP.
Effect of Protease Inhibitors on Anti-CD95 mAb-induced Deg-
radation of PARP and Lamin B—To understand the biochem-
ical nature of proteases that may be inactivated and/or sup-
pressed by Bcl-2 expression in HeLa cells, we examined the
effect of different protease inhibitors on CD95-induced cleavage
of PARP and lamin B degradation. The results in Fig. 4 show
the effects of the intracellular Ca21-chelating agent BAPTA,
the ICE family protease inhibitor YVAD-cmk, and the serine
protease inhibitor TPCK on CD95-induced cleavage of PARP
(panel A) and lamin B (panel B). Inclusion of these inhibitors at
the concentration used in Fig. 4 had no effect on the viability of
cells (data not shown). In these experiments, Bcl-2-overex-
pressing HeLa cells were used as a negative control (Fig. 4,
lanes 8 and 9). In general, BAPTA and YVAD-cmk were more
effective in inhibiting anti-CD95 mAb-triggered cleavage of
PARP (42% uncleaved in BAPTA and 94% uncleaved in 1 mM
YVAD-cmk) compared with lamin B (55% uncleaved in BAPTA
and 63% uncleaved in 1 mM YVAD-cmk). Analysis of DNA
fragmentation indicated that treatment with both BAPTA and
YVAD-cmk (but not TPCK) inhibited the CD95-induced DNA
fragmentation as expected from the previous studies (data not
shown). In brief, these results not only demonstrate the possi-
ble involvement of Ca21-sensitive cellular events and ICE fam-
ily proteases in CD95-induced cleavage of PARP and lamin B
degradation, but also indicate that these pathways may not be
active in Bcl-2-expressing cells (Fig. 4, compare lanes 9 and 8).
Bcl-2 Restores Anti-CD95 mAb-induced NF-kB Activation—
Recent studies have suggested that CD95 and TNF receptors,
FIG. 1. CD95-induced fragmentation of oligonucleosomal DNA
follows degradation of lamin B. A, DNA fragmentation. HeLa cells
were treated with anti-CD95 mAb (100 ng/ml) for 0–6 h. Ethidium
bromide staining of low molecular size DNA from 3 3 106 cells is shown.
Lane 1, [lamda] DNA (HindIII digest) molecular size marker (M); lane
2, 0 time; lane 3, 1 h; lane 4, 1.5 h; lane 5, 2 h; lane 6, 4 h; lane 7, 6 h.
B, effect of anti-CD95 mAb on lamin levels. Samples containing equal
amounts of protein (20 mg) were immunoblotted using well character-
ized chicken antibodies to lamins A and C (recognized by the same
antibody) and lamin B. As an internal control, the lamin B blot was
reprobed with an unrelated actin antibody. C, quantitation of degrada-
tion of lamins. The relative intensities of the specific lamin bands
shown in B were quantified using a protein data base scanner. Results
are presented as percent lamin contained in the specific lamin band at
the various times after anti-CD95 mAb treatment. Results shown in A
and B are from the same experiment and are representative of three
independent experiments.
FIG. 2. Bcl-2 suppresses CD95-mediated DNA fragmentation as
well as degradation of lamin B. A, shown is overexpression of Bcl-2.
Lane 1, control HeLa cells; lane 2, clone 1; lane 3, clone 7; lane 4, clone
5; lane 5, control neo clone expressing an unrelated PKR.w1 gene. B,
HeLa/Bcl-2.1 (lanes 1 and 2), HeLa/Bcl-2.7 (lanes 3 and 4), and HeLa
(lanes 5 and 6) cells were treated with (1) or without (2) anti-CD95
mAb (100 ng/ml) for 6 h. Ethidium bromide staining of low molecular
size DNA from 3 3 106 cells is shown. C, cells were treated with
anti-CD95 mAb (100 ng/ml) for 6 h. Whole cell extracts were made, and
equal amounts of protein (20 mg) were immunoblotted with antibodies
specific for different types of lamins. As an internal control, the lamin
B blot was reprobed with an unrelated actin antibody. Results shown
are representative of five independent experiments.
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despite significant homology, may utilize different signal trans-
duction pathways. In particular, TNF (but not CD95) induces
activation of NF-kB (15). Since CD95-induced apoptosis is
known to be inhibited by Bcl-2 expression, we hypothesized
that the deregulation of Bcl-2 may modulate the signal trans-
duction pathway associated with activation of CD95. We there-
fore examined the effect of anti-CD95 mAb on activation of
NF-kB in HeLa cells and the Bcl-2-overexpressing HeLa clone
using electrophoresis mobility shift assay with the nuclear
extracts (Fig. 5). Consistent with previous studies (15), no
NF-kBzDNA-bound activity was detected in HeLa cells stimu-
lated with anti-CD95 mAb (Fig. 5, lanes 1–4). Interestingly,
treatment of Bcl-2-expressing HeLa/Bcl-2.1 cells with anti-
CD95 mAb resulted in potent activation of the NF-kBzDNA
complex within 1 h (1.7-fold), which continued to increase up to
11-fold by 4 h post-treatment (Fig. 5, lanes 5–8). The observed
kB-binding complex resulted from the specific DNA-protein
interaction since it was competed by 100-fold molar excess of
unlabeled kB probe (data not shown).
We next examined the nature of NF-kB subunits in the major
NF-kBzDNA complex activated by anti-CD95 mAb in Bcl-2-
expressing HeLa cells (Fig. 6, A and B). The results of antibody
supershift experiments demonstrated that incubation of DNA-
binding mixtures with either a p50-specific (Fig. 6C, lane 2) or
a RelA-specific (lane 4) antiserum resulted in the supershift of
the kB-binding complex (Fig. 6C, indicated by arrowheads). In
contrast, the anti-CD95 mAb-inducible NF-kBzDNA complex
only sightly immunoreacted with anti-p52 serum (Fig. 6C, lane
3) and had no immunoreactivity with anti-c-Rel serum (lane 5).
Similarly, a preimmune serum did not affect the formation of
the NF-kBzDNA complex. Parallel immunoblotting analysis of
the subcellular extracts revealed that activation of the NF-
kBzDNA binding activity by anti-CD95 mAb resulted from the
induction of RelA nuclear translocation (Fig. 7A). Immunoblot-
ting of cell extracts from anti-CD95 mAb-treated HeLa cells
indicated that RelA was proteolytically degraded in these cells
(data not shown). To determine whether anti-CD95 mAb-me-
diated NF-kB was functional, we examined the expression of
NF-kB target gene products such as IkBa (35). As observed in
FIG. 3. Bcl-2 prevents CD95-mediated cleavage of PARP. A,
samples of HeLa cells treated with anti-CD95 mAb for different times
were immunoblotted with a mAb (C-2-10) against PARP. The positions
of PARP (113 kDa) and the 85-kDa proteolytic cleavage product of
PARP (85 kDa) are shown (upper panel). The relative intensities of the
upper 113-kDa PARP bands were quantified using a protein data base
scanner and are presented as percent PARP contained (uncleaved) in
the upper band at the various times after anti-CD95 mAb treatment
(lower panel). B, HeLa cells and their Bcl-2-overexpressing clones were
treated with anti-CD95 mAb (100 ng/ml) for 6 h. Cell extracts were
made and subjected to immunoblot analyses with anti-PARP mAb. An
overexposed film demonstrating the lack of the 85-kDa band in Bcl-2-
overexpressing clones is shown here. The positions of PARP and its
85-kDa cleaved fragment are shown on the right. Results shown are
representative of four independent experiments.
FIG. 4. Effect of protease inhibitors on anti-CD95-induced deg-
radation of PARP and lamin B. Cells were pretreated for 6 h with
400 mM BAPTA (lane 3); 0.25, 0.5, or 1 mM YVAD-cmk (lanes 4–6,
respectively); 100 mM TPCK (lane 7); or mock 0.1% (v/v) methanol
solvent (lane 2). Then the cells were incubated with (1) or without (2)
anti-CD95 mAb (100 ng/ml) for 2 h. All agents were dissolved in meth-
anol. Shown is the immunoblotting of cell extracts with anti-PARP mAb
(A) and anti-lamin B antibody (B). Lanes 1–7, HeLa cells; lanes 8 and 9,
HeLa/Bcl-2.1 cells. Results shown are representative of three independ-
ent experiments.
FIG. 5. Anti-CD95 mAb induces NF-kB activation. A, the paren-
tal HeLa (lanes 1–4) or Bcl-2-overexpressing HeLa/Bcl-2.1 (lanes 5–8)
cells were treated with anti-CD95 mAb (100 ng/ml) for the indicated
time periods. Nuclear extracts were prepared. Equal amounts of protein
(5 mg) were incubated with a 32P-radiolabeled kB probe, and the DNA-
protein complexes were fractionated by 5% native polyacrylamide gel
electrophoresis. The arrow indicates the position of the NF-kBzDNA
complex. B, the relative intensities of the NF-kBzDNA complex band
were quantified and are presented as -fold activation over the levels in
the control untreated cells. Results shown are representative of four
separate experiments.
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TNF-a-induced cells (35), anti-CD95 mAb potently induced the
de novo synthesis of IkBa in a time-dependent manner. Simi-
larly, anti-CD95 mAb also induced the de novo synthesis of
p105, another target gene product of NF-kB (36). In brief, these
results suggest that in Bcl-2-expressing cells, anti-CD95 mAb-
mediated signaling involves functional activation of the p50/
RelA NF-kB heterodimer, a prototypic form of NF-kB induced
by various agents including TNF-a (36).
Since CD95-induced apoptosis involves activation of ICE
family proteases (15, 18) and inclusion of the specific ICE
inhibitor YVAD-cmk is known to prevent anti-CD95 mAb-in-
duced cleavage of PARP (Fig. 4), we also determined whether
inhibition of ICE/ICE-like proteases by YVAD-cmk could re-
store activation of NF-kB by anti-CD95 mAb in HeLa cells. Our
results indicated that pretreatment (6 h) of HeLa cells with
YVAD-cmk (0.5 mM) could effectively block anti-CD95 mAb-
mediated cleavage of PARP and DNA fragmentation, but had
no effect on activation of NF-kB (data not shown), suggesting
that, perhaps, activation of NF-kB may not be an essential
early event in anti-CD95 mAb-mediated apoptosis in HeLa
cells. This view is also supported by Ponton et al. (37) (who
reported their results while this study was in progress), dem-
onstrating that activation of NF-kB by anti-CD95 mAb is not
related to the apoptotic property of CD95.
DISCUSSION
It is now well accepted that apoptosis is a normal physiolog-
ical phenomenon that plays an important role in the mainte-
nance of tissue homeostasis. Apoptosis is regulated by specific
cellular pathways including Bcl-2 and CD95, and the deregu-
lation of apoptosis contributes to the pathogenesis of a number
of human diseases including cancer. Although recent studies
have shown the inhibitory effect of Bcl-2 against anti-CD95
mAb-induced apoptosis both in vivo and in vitro (38, 39), the
possible biochemical pathways involved remain poorly under-
stood. This investigation was undertaken to examine the reg-
ulatory interactions between CD95 and Bcl-2 pathways by
studying the effects of Bcl-2 on the possible modulation of
cellular pathways activated by CD95 using HeLa cells as a
model system. We have now demonstrated that the deregula-
tion of Bcl-2 in HeLa cells is closely linked to several important
phenotypic changes including prevention of degradation of
lamin B and PARP in response to activation of cells by anti-
CD95 mAb.
To explore the biochemical basis of the protective effects of
Bcl-2 against an apoptotic signal such as CD95, we compared
the effect of anti-CD95 mAb treatment on the cleavage of
lamins and PARP in control and Bcl-2-transfected cells. In
control cells, selective degradation of lamin B and PARP was
observed to precede CD95-mediated DNA fragmentation (Figs.
1 and 3A). Interestingly, the early degradation of lamin B was
in contrast to the fate of lamins A and C, which were cleaved at
the time of internucleosomal DNA fragmentation. These re-
sults suggest that apoptotic signals may first degrade the nu-
clear components involved in protection of chromosomes, and
this in turn might promote DNA fragmentation. To our knowl-
edge, this is the first demonstration that the A-type and B-type
lamins are handled differently during CD95-mediated apopto-
sis. The basis for the differences in timing of lamin cleavage are
currently unknown. Previous studies using a cell-free system
that recapitulates the nuclear changes observed in apoptotic
nuclei have revealed that PARP is cleaved by one ICE family
protease (10), possibly CPP32 (40, 41), whereas lamins are
cleaved by another ICE family protease (7). Interestingly, the
lamin protease was more sensitive to the ICE family inhibitor
YVAD-cmk than the PARP protease in these previous cell-free
studies. The cleavage of nuclear polypeptides appears to be
more complicated in anti-CD95-treated HeLa cells. First, the
observation that lamin B is cleaved before lamins A and C in
HeLa cells raises the possibility that B-type lamins are cleaved
FIG. 6. Activation of p50/RelA NF-kB heterodimer by anti-
CD95 in HeLa/Bcl-2.1 cells. A, cells were treated with anti-CD95 mAb
(100 ng/ml) for the indicated time periods. Nuclear extracts were ana-
lyzed by EMSA as described in the legend to Fig. 6. The position of the
NF-kBzDNA complex is indicated by the arrow. B, shown is the quan-
titation of the NF-kBzDNA activation from A. C, shown is the antibody
supershift analysis of anti-CD95 mAb-induced NF-kBzDNA complex
formation. To determine the NF-kB species in the DNA-protein com-
plex, nuclear extracts (5 mg) from anti-CD95 mAb-treated (2 h) HeLa
cells were incubated for 10 min with or without specific antisera recog-
nizing different NF-kB subunits and were analyzed by EMSA. The
major supershifted bands are indicated by arrowheads. Results shown
are representative of three separate experiments.
FIG. 7. Effect of anti-CD95 mAb on nuclear translocation of
RelA and expression of target gene product IkBa. A, cytosolic (C)
and nuclear (N) extracts were made, and equal amounts of protein (20
mg) were immunoblotted with RelA antibody. B, cells were stimulated
with anti-CD95 mAb (100 ng/ml) for 6 or 3 h and metabolically labeled
with [35S]methionine during the last 1.5 h before harvesting the cells.
Lysates containing equal amounts of trichloroacetic acid-precipitable
cpm were immunoprecipitated with the IkBa-specific antiserum.
Regulatory Interactions between Bcl-2 and CD9530358
 by guest on M
arch 14, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
by one protease and A-type lamins are cleaved by a second
protease. Second, based on the differences in sensitivity to
YVAD-cmk (Fig. 4), it appears that the lamin B protease and
PARP protease are also distinct. This raises the possibility that
as many as three distinct ICE family proteases might be active
in nuclei of anti-CD95 mAb-treated HeLa cells during the
course of apoptosis. Finally, although proteolysis of PARP and
lamins in the cell-free system is insensitive to chelation of
divalent cations (7), our results show that proteolysis of these
polypeptides in anti-CD95-treated HeLa cells can be partially
inhibited by the calcium chelator BAPTA. These observations
raise the possibility that Ca21-dependent processes might play
a role in protease activation in anti-CD95 mAb-treated cells,
although the participation of Ca21-dependent proteases in the
degradation process in situ cannot be ruled out.
Recent results from several laboratories (18, 42) have indi-
cated that Bcl-2 expression prevents activation of ICE family
proteases. Consistent with these results, we observed that
Bcl-2 expression abolished CD95-mediated cleavage of the
lamins as well as PARP (Figs. 2 and 3). This work is the first to
show that Bcl-2 expression is associated with failure to cleave
major polypeptides that are cleaved in most cell types under-
going apoptosis. These results are consistent with the hypoth-
esis that Bcl-2 acts on steps that occur upstream from the
action of ICE family proteases in these cells (18). The finding
that the degradation of lamin B and PARP was completely
prevented by Bcl-2 expression (as opposed to partial inhibition
by YVAD-cmk; Fig. 4) suggests that the deregulation of Bcl-2
may inactivate not only YVAD-cmk-sensitive ICE family pro-
teases, but also other unidentified proteases that still may be
active in YVAD-cmk-treated HeLa cells stimulated with anti-
CD95 mAb.
Another notable finding in this study was the activation of
NF-kB by anti-CD95 mAb in Bcl-2-overexpressing cells. Previ-
ous studies have demonstrated that CD95-mediated signaling
does not involve activation of NF-kB (14). However, the exist-
ence of significant homology between the death domains of
CD95 and TNF receptors raises the possibility of a similar
mechanism(s) of signaling by these two receptors. It is possible
that during CD95-induced apoptosis, cellular proteolytic
changes might preclude detection of the NF-kB activation, and
in the presence of Bcl-2, which prevents proteolysis, activation
of NF-kB may be restored. We therefore examined the hypoth-
esis that Bcl-2 deregulation may modulate signal transduction
pathway(s) associated with activation of the CD95 receptor. In
agreement with the previous study (14), there was no activa-
tion of NF-kB by anti-CD95 mAb in HeLa cells. Interestingly,
anti-CD95 mAb treatment of Bcl-2-overexpressing HeLa cells
resulted in the potent early activation of NF-kB, suggesting
that the regulation of Bcl-2 could also restore the NF-kB sig-
naling by CD95. Our results also show that CD95-induced
activation of the NF-kBzDNA complex consisted of the p50/RelA
NF-kB heterodimer, a prototypic form of NF-kB induced by
various agents including TNF-a (34). Since overexpression of
Bcl-2 resulted in restoration of NF-kB activation by CD95,
these findings suggest that the observed activation of NF-kB by
CD95 may be not sufficient to result in apoptosis in HeLa cells
treated with anti-CD95 mAb. This notion is in agreement with
the earlier observations demonstrating the effectiveness of
Bcl-2 in preventing apoptosis in the absence of reactive oxygen
(24). Furthermore, our conclusion that activation of NF-kBmay
not be an essential component in anti-CD95 mAb-mediated
apoptosis in HeLa cells is also supported by the finding that
YVAD-cmk, an ICE inhibitor, effectively blocked anti-CD95
mAb-induced DNA fragmentation and PARP cleavage, but did
not allow detection of CD95-mediated activation of NF-kB in
HeLa cells. However, it is also possible that some ICE family
proteases escape inhibition by YVAD-cmk and degrade NF-kB
in the cells even in the presence of YVAD-cmk. Studies are in
progress to address these possibilities further.
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